Post
AbbVie reports findings from giant cell arteritis therapy trial
AbbVie has revealed positive top-line outcomes from the first period of the Phase III SELECT-GCA study of upadacitinib (RINVOQ; 15 …
Cerevel reports positive data from Phase III Parkinson’s treatment trial
Cerevel Therapeutics has reported positive topline results from its Phase III TEMPO-3 clinical trial evaluating a once-a-day dose of tavapadon …
Leading cybersecurity companies in clinical trials
Clinical trial software is vulnerable to breaches and ransomware attacks, as clinical trials become more decentralised and incorporate the use …
AAN 2024: Four-year follow-up of Roche’s PRX-002 encouraging for Parkinson’s disease
There are currently no marketed disease-modifying therapies (DMTs) for Parkinson’s disease (PD). Key opinion leaders (KOLs) previously interviewed by GlobalData, …
AAN 2024: new pooled data highlights efficacy of Axsome Therapeutics’s AXS-07
On 15 April, at the American Academy of Neurology (AAN) 2024, Axsome Therapeutics presented new pooled data from two Phase …
gaitQ and machineMD secure $1m to kickstart Parkinson’s movement study
Oxford-based start-up gaitQ and Swiss medical device company machineMD have been awarded a $1m grant from InnovateUK and Innosuisse to …
Artiva doses first subject in Phase I lupus nephritis treatment trial
Artiva Biotherapeutics has announced dosing of the first subject in the Phase I clinical trial of AlloNK (AB-101), a natural …
Roche’s OCREVUS SC shows promise in Phase III multiple sclerosis trial
Roche has reported data from the Phase III OCARINA II study of a subcutaneous (SC) injection of OCREVUS (ocrelizumab) in …
Joincare Pharmaceutical meets primary endpoint in Phase III flu trial
Chinese-based Joincare Pharmaceutical has met the primary endpoint in a Phase III trial of its partnered flu candidate TG-1000. Taiwan-based TaiGen …
Hyperfine starts enrolment in portable imaging workflow study
US-based health technology company Hyperfine has enrolled the first patient in the clinical workflow study of its US Food and …
Eli Lilly’s tirzepatide reduces sleep apnoea severity in Phase III trials
Eli Lilly and Company has announced positive topline results from the SURMOUNT-OSA Phase III clinical trials, indicating that its tirzepatide …
GSK reports positive data from Phase III gonorrhoea antibiotic trial
GSK has announced positive data from the Phase III EAGLE-1 clinical trial of gepotidacin, an investigational oral bactericidal triazaacenaphthylene antibiotic, …
AAN 2024: AbbVie highlights long-term safety of atogepant in migraine prevention
At the American Academy of Neurology (AAN) 2024, AbbVie highlighted the long-term safety data of Qulipta (atogepant) for the preventive …
AAN 2024: Biomarker data shows promise for Alzheon’s oral anti-amyloid drug
On 15 April at the American Academy of Neurology (AAN) 2024 Annual Meeting, during a scientific platform session titled 'Emerging …
AAN 2024: Amneal showcases IPX203’s safety profile in anticipation of FDA approval
At the American Academy of Neurology (AAN) 2024 Annual Meeting, Amneal Pharmaceuticals presented new safety data for IPX203 (carbidopa + …